



(51) International Patent Classification:

A61K 9/50 (2006.01) *A61K 31/60* (2006.01)
A61K 31/40 (2006.01) *A61P 9/00* (2006.01)
A61K 31/403 (2006.01)

(21) International Application Number:

PCT/EP2014/061735

(22) International Filing Date:

5 June 2014 (05.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13170909.9 6 June 2013 (06.06.2013) EP

(71) Applicants: **FERRER INTERNACIONAL, S.A.**
[ES/ES]; Gran via Carles III, 94, E-08028 Barcelona (ES).
FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
[ES/ES]; C/ Melchor Fernández Almagro, 3, E-28029 Madrid (ES).

(72) Inventors: **MARTIN SANZ, Pablo**; C/ Joan Buscallà, 1-9, E-08173 Sant Cugat Del Vallès (ES). **URBANO HURTADO, Javier**; C/ Joan Buscallà, 1-9, E-08173 Sant Cugat Del Vallès (ES).

(74) Agent: **ZBM PATENTS - ZEA, BARLOCCI & MARKVARSDEN**; Pl. Catalunya, 1 2nd floor, ES-08002 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KN, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

(57) Abstract: The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases.

